Mostrando 2 resultados de: 2
Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome
ArticleAbstract: Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feePalabras claves:anorexia nervosa, Orexin-A, Partial hospitalization, Sleep, treatment outcomeAutores:Baños R.M., Beckmann J.S., Botella C., Casanueva F.F., Crujeiras A.B., Custal N., Estivill X., Fernández-García J.C., Fernández-Real J.M., Fernández‐aranda F., Frühbeck G., Garrido-Sanchez L., Israel M., Menchón J.M., Murcia S.J., Ortega F.J., Riesco N., Rodríguez A., Roser Granero, Sánchez‐díaz I., Sauchelli S., Steiger H., Tàrrega S., Tinahones F.J., Torre R.d.l.Fuentes:scopusLiver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD
ArticleAbstract: The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the globPalabras claves:AAV, CPT1A, fatty-acid oxidation, Gene therapy, hepatic steatosis, lipid biomarker, obesityAutores:Alonso S., Bartrons R., Calderón-Domínguez M., Casals N., Casas J., Escolà-Gil J.C., Frühbeck G., Fucho R., Herrero L., Llorente-Cortes V., Mera P., Mir J.F., Montironi C., Rodríguez A., Salvador J., Sánchez-Infantes D., Sandra Recalde, Sebastián D., Serra D., Soler-Vázquez M.C., Valentí V., Weber M., Zorzano A.Fuentes:scopus